BMS-955176

BMS-955176
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1392312-45-6;
ChemSpider	58922159;
UNII	4CA9IAU7RJ;
CompTox Dashboard (EPA)	DTXSID401336145 ;
Chemical and physical data
Formula	C42H62N2O4S
Molar mass	691.03 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7;
	InChI InChI=1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1; Key:XDMUFNNPLXHNKA-ZTESCHFWSA-N;

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.^[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been designed to better tolerate gag polymorphisms.^[2]^[3]

Studies

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).^[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.^[4]^[5]

It appears that development of BMS-955176 has been terminated.^[6]